Search Results for "indomethacin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for indomethacin. Results 1 to 4 of 4 total matches.
See also: Indocin, Tivorbex

Comparison Table: Some Drugs for Gout (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
of symptoms No evidence that indomethacin, a traditional choice, is more effective than other NSAIDs Can ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9   doi:10.58347/tml.2023.1688c |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
NSAIDs.15 The potent NSAID indomethacin is associated with a high risk of GI adverse effects; it should ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
that indomethacin (Indocin, and others), a traditional choice that has a relatively high incidence of adverse ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Dasiglucagon (Zegalogue) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
anti-inflammatory drug (NSAID) indomethacin, which inhibits pancreatic release of glucagon ...
The FDA has approved dasiglucagon (Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require reconstitution before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi, an intranasal powder approved for use in patients ≥4 years old, have been available since 2019. Injectable glucagon emergency kits (GlucaGen HypoKit, and generics) have been available for years, but they require...
Med Lett Drugs Ther. 2021 Aug 23;63(1631):132-4 |  Show IntroductionHide Introduction